Five-year efficacy and safety of pembrolizumab as first-line treatment in patients with non-small cell lung cancer with PD-L1 tumor proportion score ≥50 %: A multicenter observational study

Lung, Respiratory and Thoracic Cancer
Do you want to read an article? Please log in or register.